Atlas Effectors of Anti-Tumor Immunity

166 Pages·2008·29.861 MB·English

by  Joseph G. Sinkovics (auth.), Mikhail V. Kiselevsky (eds.)

K Mikhail V. Kiselevsky
i
s
e Editor
l
e
v
s
k
y

E
d
.
Atlas Eff ectors
(cid:2)
of Anti-Tumor
A
t
l
a
s Immunity

E
f

e
c
t
o
r
s

o
f

A
n
t
i
-
T
u
m
o
r

I
m
m
u
n
i
t
y
(cid:5)(cid:6)฀(cid:4)
Atlas
Effectors of Anti-Tumor Immunity
Atlas
Effectors of Anti-Tumor Immunity
Editor
Mikhail V. Kiselevsky
NN Blokhin Russian Cancer Research Center RAMS, Moscow, Russia
Editor
MikhailV.Kiselevsky
LaboratoryofCellImmunity
NNBlokhinRussianCancer
ResearchCenter
RussianAcademyofMedicalSciences
Kashirskoeshosse24
Moscow
Russia115478
ISBN: 978-1-4020-6930-7 e-ISBN: 978-1-4020-6931-4
LibraryofCongressControlNumber:2007939885
©2008SpringerScience+BusinessMediaB.V.
Nopartofthisworkmaybereproduced,storedinaretrievalsystem,ortransmitted
inanyformorbyanymeans,electronic,mechanical,photocopying,microfilming,recording
orotherwise,withoutwrittenpermissionfromthePublisher,withtheexception
ofanymaterialsuppliedspecificallyforthepurposeofbeingentered
andexecutedonacomputersystem,forexclusiveusebythepurchaserofthework.
Printedonacid-freepaper.
9 8 7 6 5 4 3 2 1
springer.com
Table of Contents
Preface vii
List of Contributors ix
1. Adoptive immunotherapy for human cancers: Flagmen signal first “open road”
then “roadblocks.” A narrative synopsis 1
Joseph G. Sinkovics
2. Tumor microenvironment genesis and implications on cancer immune response 25
Gianfranco Baronzio and Isabel Freitas
3. Natural killer cells. Lymphokine-activated killers 45
Irina Zh. Shubina, Olga V. Lebedinskaya, Evgenia O. Khalturina, Irina O. Chikileva
and Mikhail V. Kiselevsky
4. CD4+/CD25+ T-regulatory cells 65
Irina Zh. Shubina, Nadezhda P. Velizheva and Mikhail V. Kiselevsky
5. CD8+ CD57+ T cells in tumor immunology 73
María I. Sada-Ovalle
6. Natural killer T (NKT) cells: Immunophenotype, functional characteristics
and significance in clinical practice 81
Olga V. Lebedinskaya, Nelly K. Akchmatova, Irina O. Chikileva, Irina Zh. Shubina
and Mikhail V. Kiselevsky
7. LAK immunotherapy in clinical studies 101
Irina Zh. Shubina, Lev V. Demidov, Irina O. Chikileva, Olga V. Lebedinskaya
and Mikhail V. Kiselevsky
v
vi Table of Contents
8. Major properties of dendritic cells and their actual and potential applications
in cancer therapy and infectious disease prophylaxis 111
Irina O. Chikileva, Natalia Yu. Anisimova, Olga V. Lebedinskaya,
Mikhail V. Kiselevsky and Vyacheslav M. Abramov
Index 161
Preface
Traditional understanding of anti-tumor of anti-tumor defense is assigned to other
immunity is based on the theory of immuno- effectors of innate immunity as well, first
logical surveillance and it suggests function of all, as potential NK activators, such as
of cytotoxic lymphocytes that can recognize dendriticcellsandnaturalkillerT-cells.Along
tumor-specific antigens and lyse malig- withthementionedfunctionsinnateimmunity
nantly transformed cells. However tumor effectors can have a negative regulatory effect
development is not the direct result of on anti-tumor immuno-biological surveillance
immune system disorders and even in by secreting Th2 cytokines. Contemporary
case of marked immuno-deficiencies, in standpoints in understanding mechanisms of
particular, in patients – transplant recipients, innate and adaptive immunity are the basis
immune dysfunction does not always lead for development and improvement various
to higher cancer incidence comparing with methods of adoptive immunotherapy.
total population. This phenomenon may be Anti-tumor immunity has been subject of
explained by the concept of immuno-editing, most thorough interest and detailed investi-
which suggests that anti-tumor immunity gation over the last decades. Nowadays more
effectors can not only protect the organism and more specialists in medicine and adjacent
from tumor development, but also select low areas face the problem of immuno-biological
immunogenic clones of transformed cells that surveillance function. Research data on this
can escape from immuno-biological surveil- issue are diverse and extensive. In numerous
lance. Mechanism of avoiding the immune monographs, educational books and scien-
attack is primarily due to the lack of tific papers a keen reader can find practi-
specific antigens on tumor cell surface and cally any material concerning the questions
loss or down-regulation of expression rate of interest. The purpose of the present
of molecules of major histocompatibility publication is to convey considerably full
complex, which are necessary factors for and up-to-date information to the reader
initiation of adaptive immune response and in a reasonably comprehensible format. To
generation of antigen-specific T-lymphocytes. make the material easy for perception the
Therefore recent data have more often given Atlas has a large number of illustrative
evidence in favor of innate immunity being pictures,whichalsohelptotrackinterrelations
themainweaponofimmunesurveillanceover between morphological features of anti-tumor
tumordevelopment.AndNKsplaythecrucial immunity effectors and their phenotype and
role as they can recognize and lyse trans- functional characteristics. The Atlas is aimed
formedcellsinMHCandantigenindependent at a wide audience of students and teachers
manner. An important part in realization of medical and biology faculties, specialists
vii
viii Preface
of research laboratories and diagnostics The Atlas comprises over 200 figures and
centers, practicing oncologists and immunol- schemes referring to effectors of anti-tumor
ogists, as well as physicians of different immunityandmethodsofanti-canceradoptive
specializations. immunotherapy.
List of Contributors
Vyacheslav M. Abramov Mikhail V. Kiselevsky
Institute Immunological Engineering Moscow Region, NN Blokhin Russian Cancer Research Center RAMS,
Russia Laboratory of Cell Immunity, Moscow, Russia
Nelly K. Akchmatova Olga V. Lebedinskaya
II Metchnikov Research Institute of Vaccines and EAVagner Perm Medical Academy, Departtament of
Serums, Laboratory of Therapeutic Vaccines, Histology, Embryology and Cytology Perm, Russia
Moscow, Russia
María I. Sada-Ovalle
Nathalie Yu. Anisimova
Research Unit, Biochemistry Department, National
NN Blokhin Russian Cancer Research Center RAMS,
Institute of Respiratory Diseases, Calzada de Tlalpan
Laboratory of Cell Immunity, Moscow, Russia
4502, Col. Sección XVI, Delegación Tlalpan, México
D.F., Mexico
Gianfranco Baronzio
Family Medicine Area ASL1 Legnano (Mi) and
Irina Zh. Shubina
Radiotherapy, Hyperthermia Service, Policlinico di
Monza, Monza, Italy NN Blokhin Russian Cancer Research Center RAMS,
Moscow, Russia
Irina O. Chikileva
NN Blokhin Russian Cancer Research Center RAMS, Joseph G. Sinkovics
Laboratory of Cell Immunity, Moscow, Russia St.Joseph’sHospital’sCancerInstituteAffiliatedwith
the H. L. Moffitt Comprehensive Cancer Center at the
Lev V. Demidov University of South Florida College of Medicine;
NN Blokhin Russian Cancer Research Center RAMS, Department of Medical Microbiology & Immunology,
Department of Biotherapy, Moscow, Russia the University of South Florida College of Medicine,
Tampa FL, USA
Isabel Freitas
University of Pavia, Department of Animal Biology
Nadezhda P. Velizheva
and IGM-CNR Center for Histochemistry and
NN Blokhin Russian Cancer Research Center RAMS,
Cytometry, Pavia, Italy
Moscow, Russia
Evgenia O. Khalturina
I.M. Setchenov Medical Academy, Departtament of
Microbiology, Virusology and Immunology Moscow,
Russia
ix
The Atlas Effectors of Anti-Tumor Immunity activity is associated with the development
was published with the financial support of of international science projects. Since 1994,
The International Science and Technology the ISTC has managed financial support
Center (ISTC). Chapters 3–8 have been exceeding USD 769M to 2500 projects,
written by the participants of ISTC-supported encompassing over 70,000 scientists and
projects. This publication has been produced technicians at more than 700 institutes in
with the financial assistance of the European Russia and CIS. The ISTC also provides a
Union as a Funding Party to the Agreement tax and customs-duty exempt mechanism for
establishing the ISTC. its 370 commercial and governmental agency
The International Science and Technology Partners to fund research with ISTC benefi-
Center is an intergovernmental organization ciary institutes. Biotechnology is the most
holding diplomatic status, created to prevent dynamically evolving direction of the ISTC
nuclear weapons proliferation, contribute to activity, with over 640 projects totaling USD
global security, and to link the demands of 202M.
international markets with the exceptional The ISTC has established strategic partner-
pool of scientific talent available in Russian ships with Russian and CIS innovation
and other Commonwealth of Independent foundations and organizations, has engaged
States (CIS) institutes. The ISTC was estab- in technology transfer using its interna-
lished in 1992 by the European Union, Japan, tionally agreed procedures, and has assisted a
the Russian Federation, and the United States broad range of other international institutions,
of America on the basis of a multinational government organizations, universities, and
agreement. Canada joined as a full Governing thescientificcommunityasawhole,todeliver
Board member in 2004. The ISTC’s core their R&D and commercialization objectives.
Contact details
Steve Bourne
Communications Manager
Krasnoproletarskaya ul. 32-34, ISTC
P.O. Box 20, 127473 Moscow,
Russian Federation
Email: [email protected]
Office: (7-495) 982 3141
Web site www.istc.ru
xi